On the other hand, as a result of a natural reaction of the immune system against invading pathogenic viruses and bacteria, thrombi fulfil an important physiologicalNormal functioning, not abnormal. function by inhibiting their spread in the body and contributing to their elimination (immunothrombosis).
A central role in immunothrombosis is played by neutrophilic granulocytes which, after activation, release a network of extracellular fibres consisting mainly of DNA, histones and granular proteins (neutrophil extracellular traps, NETs). These net-like structures are able to bind pathogenic germs and render them harmless. At the same time, they have a prothrombotic effect by inactivating anticoagulant substances such as the tissue factor pathway inhibitor.
However, if there is an excessive immune reaction, such as in sepsisAlso colloquially called blood poisoning, it is a generalised infection and inflammatory reaction of the body affecting the whole body. The pathogens, mainly bacteria, can be detected from the blood., the resulting thromboses can lead to serious organ damage. Some tumour diseases are also associated with an increased risk of thrombosisFormation of a blood clot (thrombus) in a blood vessel., which can be attributed to the immune reaction against the tumour tissue, among other things.
The risks of thrombosis-induced damage associated with efficient defence against pathogenic agents highlights the need for complex regulatory mechanisms of immunothrombosis and processes coupled with it. A multitude of messenger substances and subcellular components (microvesicles, exosomes) are involved in this, with which various cells of the immune system, the blood coagulation system and the vascularConcerning the blood vessels. system exert mutual influence.
The aim of our research is to identify relevant proteins and enzymes and to investigate their role in the development of immunothrombosis. In this way, we want to contribute to the improvement of diagnostic and therapeutic methods of cardiovascular, infection and tumour-associated thromboembolism.
